Opinion

Video

Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment

Author(s):

Nathalie Albert, MD ,Matthias Preusser, MD

Medical experts engage in a discussion on the PET RANO 1.0 Response Criteria, which provides guidelines for evaluating treatment response in patients with brain tumors, taking into account both measurable PET-positive disease and non-PET-positive disease, as assessed through initial baseline imaging and subsequent follow-up scans.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
2 experts in this video
2 experts in this video
Related Content
Renal Cell Carcinoma | stock.adobe.com
December 13th 2024

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

Diffuse Glioma
November 25th 2024

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

Mirdametinib in Adult and Pediatric NF1-PN | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

Larotrectinib in TRK Fusion+ CNS Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 24th 2024

Larotrectinib Induces Rapid, Durable Responses in Pediatric Patients With TRK Fusion+ CNS Tumors

Tovorafenib in Pediatric BRAF-Altered R/R Low-Grade Glioma | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 23rd 2024

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma